Press release
Global PARP Inhibitor Market: Size, Trends and Forecasts 2016-2020: Company Coverage - Tesaro, AbbVie, Medivation, AstraZeneca, Clovis Oncology
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as it is the only commercialized product in the market. The clinical trials of Niraparib, Rucaparib, Talazoparib and Veliparib are also summarized along with the anticipated market commencement for each of the products.
The report provides detailed market potential of PARP inhibitor in Ovarian cancer, Breast cancer, Prostate cancer and Pancreatic cancer. This section provides the detailed analysis of the clinical trials of various PARP inhibitors for the concerned cancer treatment.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=866444
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global PARP inhibitor market has also been forecasted for the period 2016-2020, taking into consideration the research & development, the growth drivers and the current and future trends. The competition in the global PARP inhibitor market is stiff and dominated by the big players like AstraZeneca. Further, key players in the market, AbbVie, Clovis Oncology, Medivation and Tesaro are also profiled with their financial information and respective business strategies.
Regional Coverage
Global
Company Coverage
AstraZeneca PLC
AbbVie Inc.
Clovis Oncology, Inc.
Medivation, Inc.
Tesaro, Inc.
Browse more details @ http://www.researchmoz.us/global-parp-inhibitor-market-size-trends-and-forecasts-2016-2020-report.html
Table of Content
1. Executive Summary
2. Introduction
2.1 DNA Damage Response (DDR)
2.2 DNA Damage Response (DDR) Drug Portfolio
2.3 PARP Inhibitor
2.3.1 Introduction to PARP Inhibitor
2.3.2 Inhibiting PARP Mechanism
2.3.3 PARP Inhibitor as a Cancer Treatment
2.3.4 PARP Inhibitor Development
3. Global Market Analysis
3.1 Global PARP Inhibitor Market by Value
3.2 Global PARP Inhibitor Market by Segments
3.2.1 Global Lynparza Market Analysis
Ongoing Lynparza Trials
Global Lynparza Market by Value
Global Lynparza Market by Region
3.2.2 Global Niraparib Market Analysis
Ongoing Niraparib Trials
Global Niraparib Market by Value
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global PARP Inhibitor Market: Size, Trends and Forecasts 2016-2020: Company Coverage - Tesaro, AbbVie, Medivation, AstraZeneca, Clovis Oncology here
News-ID: 700729 • Views: …
More Releases for Lynparza
ER+/HER2 Breast Cancer Market: Epidemiology, Pipeline Products, Companies Workin …
DelveInsight's "ER+/HER2 Breast Cancer - Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the ER+/HER2 Breast Cancer, historical and forecasted epidemiology as well as the ER+/HER2 Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Emerging therapies for ER+/HER2 breast cancer-such as KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171/GDC-9545), Camizestrant (AZD9833), LY3484356…
ER+/HER2- Breast Cancer Market: Analysis of Epidemiology, Pipeline Products, and …
ER+/HER2- Breast Cancer emerging therapies such as KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others are expected to boost the ER+/HER2- Breast Cancer Market in the upcoming years.
DelveInsight has launched a new report on "ER+/HER2- Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2032" that delivers an in-depth understanding of the ER+/HER2- Breast Cancer, historical and forecasted epidemiology…
LYNPARZA Poised for Remarkable Market Expansion of Pancreatic Cancer by 2032
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on LYNPARZA (AstraZeneca and Merck) providing insights into the drug market landscape and market forecast of LYNPARZA upto 2032. The report, titled "LYNPARZA Market Market Size, Forecast, and Drug Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of LYNPARZA in 2032?…
PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Size, Share, Growth, Analysi …
PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor revenue was US$ 4686.4 million in 2022 and is forecast to a readjusted size of US$ 8571.2 million by 2029 with a CAGR of 8.9% during the forecast period (2023-2029).
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-19N16014/Global_and_India_PARP_Poly_ADP_Ribose_Polymerase_Inhibitor_Market_Report_Forecast_2023_2029
and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for…
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Extend at a Si …
As per DelveInsight, the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market therapeutics market is anticipated to grow in the coming years owing to the expected rising prevalence of prostate cancer cases due to rapidly aging population, growing awareness of mCRPC among people, the rise in the number of companies taking interest in the development of specific drugs for mCRPC, and the market penetration of already approved drugs for prostate cancer in…
Robust Growth Visible for Electronic Drug Delivery Systems Market 2020-2025 | Me …
The exclusive research report on the Global Electronic Drug Delivery Systems Market 2020 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Electronic Drug Delivery Systems Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.
Overview of Global Electronic Drug Delivery Systems Market:
This report studies the Global…
